How the Brain's Opioid Peptides and Cannabinoid Systems Work Together in Reward and Addiction
Knockout mouse studies reveal that the endogenous opioid peptide system and the cannabinoid system interact extensively in the brain's reward circuitry, suggesting combined therapeutic targets for treating addiction.
Quick Facts
What This Study Found
The review demonstrates that the endogenous opioid system — operating through mu, delta, and kappa receptors activated by peptide ligands (enkephalins, endorphins, and dynorphins) — and the endocannabinoid system share extensive overlap in brain reward circuitry. Both receptor families are G protein-coupled and expressed throughout reinforcement pathways.
Genetic knockout studies in mice have been instrumental in dissecting the specific roles of each receptor and ligand in reward processing. The evidence points to significant functional interactions between these two systems, meaning manipulating one system can alter the other's effects on reward-related behavior.
Key Numbers
How They Did This
This is a review article that synthesizes findings from studies using genetically modified (knockout) mice. The approach examines what happens to reward-related behaviors when specific genes for opioid receptors, opioid peptides, cannabinoid receptors, or endocannabinoid enzymes are deleted, allowing researchers to identify each component's contribution in living animals.
Why This Research Matters
Addiction remains one of the most challenging public health problems, and current treatments often target only one system at a time. Understanding how opioid peptides and cannabinoids interact in the reward circuit could lead to more effective combination therapies that address addiction through multiple pathways simultaneously.
The Bigger Picture
This review bridges two of the most studied neuromodulatory systems in neuroscience. The opioid peptide system has been a target for pain management and addiction treatment for decades, while the cannabinoid system has gained attention more recently. Understanding their crosstalk is essential as both opioid and cannabis use disorders continue to grow, and combination pharmacological strategies may offer better outcomes than targeting either system alone.
What This Study Doesn't Tell Us
As a review, this paper does not present new experimental data. The findings are based primarily on mouse knockout studies, which may not fully translate to human physiology. Knockout models can also produce compensatory changes during development that complicate interpretation. The abstract does not discuss specific quantitative outcomes from the reviewed studies.
Questions This Raises
- ?Could drugs that simultaneously modulate both opioid peptide and cannabinoid receptors be more effective for addiction treatment than single-target approaches?
- ?How do compensatory mechanisms in knockout mice limit the translational value of these findings for human addiction therapy?
- ?Which specific opioid-cannabinoid receptor pairings show the strongest interactions in reward processing?
Trust & Context
- Key Stat:
- Two interacting systems The endogenous opioid peptide system (3 receptors, 3 peptide families) and the endocannabinoid system (2 receptors) converge on shared brain reward circuitry
- Evidence Grade:
- This is a narrative review of preclinical (animal) studies. While it provides a comprehensive synthesis of knockout mouse research, it does not include new data, systematic methodology, or human clinical evidence. Reviews of animal studies occupy a foundational but lower tier in the evidence hierarchy.
- Study Age:
- Published in 2015, this review captures a decade of knockout mouse research. While the fundamental biology remains relevant, newer studies may have expanded on the therapeutic strategies discussed here.
- Original Title:
- Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies.
- Published In:
- Frontiers in pharmacology, 6, 6 (2015)
- Authors:
- Befort, Katia
- Database ID:
- RPEP-02582
Evidence Hierarchy
Frequently Asked Questions
What are endogenous opioid peptides?
Endogenous opioid peptides are natural pain-relieving and mood-regulating chemicals produced by your body. The three main families are enkephalins, endorphins, and dynorphins. They activate opioid receptors (mu, delta, and kappa) in the brain and body, influencing pain perception, pleasure, reward, and mood.
Why use knockout mice to study reward and addiction?
Knockout mice have specific genes permanently deleted, allowing researchers to observe what happens when a particular receptor or peptide is absent. This reveals each component's role in reward behavior more precisely than drugs alone, which often affect multiple targets. By removing one piece at a time, scientists can map the contribution of each opioid and cannabinoid system component.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02582APA
Befort, Katia. (2015). Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies.. Frontiers in pharmacology, 6, 6. https://doi.org/10.3389/fphar.2015.00006
MLA
Befort, Katia. "Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies.." Frontiers in pharmacology, 2015. https://doi.org/10.3389/fphar.2015.00006
RethinkPeptides
RethinkPeptides Research Database. "Interactions of the opioid and cannabinoid systems in reward..." RPEP-02582. Retrieved from https://rethinkpeptides.com/research/befort-2015-interactions-of-the-opioid
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.